Skip to main navigation
Caladrius
Caladrius
  • Contact Us
Active Clinical Trials
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Pipeline
    • Overview
    • Coronary Microvascular Dysfunction (CMD) XOWNA®
    • Critical Limb Ischemia (CLI) CLBS12 (HONEDRA® in Japan)
    • Chronic Kidney Disease (CKD) CLBS201
    • No-Option Refractory Disabling Angina (NORDA) CLBS14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CD34+ Cell Technology
    • Publications
  • Careers
    • Overview
    • Job Opportunities
  • Investors & News
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
      • Media Coverage
    • Financials & Filings
      • Quarterly Results
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Corporate Governance
      • Docs & Charters
      • Management
      • Board of Directors
    • Investor Resources
      • Stockholder Information
      • Investor FAQs
      • Email Alerts
      • IR Contact
      • Disclosures
  • Patients & Families
    • Overview
    • Coronary Microvascular Dysfunction Symptoms & Treatment
    • Critical Limb Ischemia Symptoms & Treatment
  • Careers
    • Overview
    • Job Opportunities
Investors & News / Financials & Filings / Investors & News / SEC Filings / D /

SEC Filing Details

Document Details

Form
D
Filing Date
Jul 1, 2009
Document Date
Jul 1, 2009
Filing Group
Other
Company
Caladrius Biosciences, Inc.
Issuer
CALADRIUS BIOSCIENCES, INC.
  • Print Page
  • RSS Feeds
  • Email Alerts
Caladrius
Caladrius
Active Clinical Trials
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Pipeline
    • Overview
    • Coronary Microvascular Dysfunction (CMD) XOWNA®
    • Critical Limb Ischemia (CLI) CLBS12 (HONEDRA® in Japan)
    • Chronic Kidney Disease (CKD) CLBS201
    • No-Option Refractory Disabling Angina (NORDA) CLBS14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CD34+ Cell Technology
    • Publications
  • Careers
    • Overview
    • Job Opportunities
  • Investors & News
    • Overview
    • News & Events
    • Financials & Filings
    • Stock Information
    • Corporate Governance
    • Investor Resources
  • Patients & Families
    • Overview
    • Coronary Microvascular Dysfunction Symptoms & Treatment
    • Critical Limb Ischemia Symptoms & Treatment
  • Careers
    • Overview
    • Job Opportunities
  • Facebook
  • Twitter
  • LinkedIn
Join Our Email List

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100

© 2022 Caladrius Biosciences, Inc. All rights reserved.
  • Site Map
  • Privacy Policy

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100